PTN News

  • Sildenafil safety studied for premature infants with bronchopulmonary dysplasia January 18, 2018 The Pediatric Trials Network (PTN), with support from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is conducting an interventional study to examine the safety and efficacy of sildenafil in treating bronchopulmonary dysplasia (BPD) in premature infants. BPD is a common chronic lung disease that can affect premature newborns, often leading to ...
  • PTN captures valuable anthropometric data for infants January 8, 2018 The Pediatric Trials Network (PTN) conducted a study in 2015 to capture anthropometric data on pre-term and full-term infants up to 90 days old. An article on the study, An Anthropometric Survey of U.S. Preterm and Full-Term Neonates, was published in the journal Annals of Human Biology last month. “Anthropometric data are invaluable for informing the ...
  • PTN investigator to retire at end of 2017 November 17, 2017   In 2004, Dr. Ram Yogev, Director of the Section on Pediatric, Adolescent and Maternal HIV Infection at the Ann & Robert H. Lurie Children’s Hospital of Chicago, was invited to serve on an FDA advisory committee on anti-retroviral, anti-fungal and anti-tuberculosis drugs. As the only pediatrician on the committee, he was surprised to see that ...
  • Nov. 17 marks World Prematurity Day November 14, 2017 Friday, November 17th marks World Prematurity Day. Part of the March of Dimes’ Prematurity Campaign, the event is designed to raise awareness of the problem of premature birth and to support ongoing efforts to reduce rates of premature birth in the United States and around the world. According to the March of Dimes, roughly 10 percent ...
  • PTN determines appropriate TMP/SMX dosing in infants and children November 13, 2017 The Pediatric Trials Network (PTN), with funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), recently completed a multicenter study of trimethoprim/sulfamethoxazole (TMP/SMX) to determine appropriate dosing for infants and children. The results of the study were published in the journal Antimicrobial Agents and Chemotherapy on Oct. 30. TMP/SMX is ...
  • PTN study contributes to successful treatment of MRSA abscess in preterm infant November 7, 2017 Early this summer, Lucas,* a one-month-old infant born 9 weeks prematurely, was receiving routine respiratory support in the neonatal intensive care unit at the University of North Carolina Children’s Hospital when he suddenly developed a dangerous neck abscess. Upon testing, the infection was found to be caused by methicillin-resistant Staphylococcus aureus (MRSA) bacteria. Staphylococcus infections ...
  • DCRI and partners awarded FDA grant to create Global Pediatric Clinical Trials Network October 17, 2017 The Duke Clinical Research Institute and its strategic partners have been awarded a grant from the U.S. Food and Drug Administration (FDA) to establish a coordinating center for a Global Pediatric Clinical Trials Network (G-PCTN). The G-PCTN will support efficient pediatric clinical trials worldwide by developing scientific and operational infrastructure, fostering collaborative networks, sharing knowledge, ...
  • PTN Post: Issue 20 (July 2017) July 7, 2017 Check out the July 2017 issue of the PTN Post, the newsletter for the Pediatrics Trials Network — this issue highlights new research and new recommendations for pediatric research. We hope you enjoy it, and as always, we welcome your comments and feedback.
  • POPS Paradigm Explained August 25, 2016 PTN studies managed via the POPS paradigm seek to determine the appropriate dosing of understudied drugs in children by using samples collected as part of regular care (for example, blood draws). The data collected provides valuable pharmacokinetic and dosing information for drugs in different pediatric age groups and special pediatric populations (such as obese children). Dr. ...
  • SCAMP Enrollment is Wrapping Up August 25, 2016 Two years ago, the study site at the University of Florida–Jacksonville Shands Medical Centerwe enrolled SCAMP’s first patient. With remarkable effort from more than 50 study sites, including 5 in Canada, SCAMP will close enrollment by the end of 2016. Once the enrollment period ends, the study team will analyze the data and submit the clinical study report.